| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000020861 |
| Receipt No. | R000024078 |
| Official scientific title of the study | Multicenter Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer; the HGCSG1401 Study |
| Date of disclosure of the study information | 2016/02/03 |
| Last modified on | 2017/02/03 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Multicenter Retrospective Cohort Study Evaluating the Safety and Efficacy of Regorafenib in Patients with Metastatic Colorectal Cancer; the HGCSG1401 Study | |
| Title of the study (Brief title) | Multicenter Retrospective Cohort Study of Regorafenib; the HGCSG1401 Study | |
| Region |
|
|
| Condition | ||
| Condition | Colorectal Cancer | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy and safety of daily practice use of Regorafenib for patients with metastatic or unresectable colorectal cancer. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Overall Survival |
| Key secondary outcomes | Progression-free survival, Response rate, Disease control rate, Time to treatment failure, Adverse events, Relative dose intensity, Detail of subsequent treatment |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients who were treated with Regorafenib.
2) Histologically confirmed colorectal adenocarcinoma 3) Unresectable metastatic or local advanced colorectal cancer 4) Age <=20 years old |
|||
| Key exclusion criteria | 1) Active double cancers | |||
| Target sample size | 200 | |||
| Research contact person | |
| Name of lead principal investigator | Yoshito Komatsu |
| Organization | Hokkaido University Hospital |
| Division name | Cancer Center |
| Address | Kita-14, Nishi-5, Kita-ku, Sapporo, Hokkaido |
| TEL | 011-716-1161 |
| ykomatsu@med.hokudai.ac.jp | |
| Public contact | |
| Name of contact person | Satoshi Yuki |
| Organization | Hokkaido University Hospital |
| Division name | Gastroenterology and Hepatology |
| Address | Kita-14, Nishi-5, Kita-ku, Sapporo, Hokkaido |
| TEL | 011-716-1161 |
| Homepage URL | |
| satoshi-yuuki175@joy.ocn.ne.jp | |
| Sponsor | |
| Institute | Hokkaido Gastrointestinal Cancer Study Group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Hokkaido Gastrointestinal Cancer Study Group |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | NTT東日本札幌病院(北海道), 市立函館病院(北海道), 札幌医科大学(北海道), 苫小牧市立病院(北海道), 斗南病院(北海道), 弘前大学(青森県), 札幌東徳洲会病院(北海道), 北海道大学病院(北海道), 岩見沢市立総合病院(北海道), 東京大学病院(東京都), 市立札幌病院(北海道), 手稲渓仁会病院(北海道), 秋田赤十字病院(秋田県), 恵佑会札幌病院(北海道), 函館中央病院(北海道), 苫小牧日翔病院(北海道), 長崎大学病院(長崎県), 釧路労災病院(北海道), 北海道消化器科病院(北海道), 札幌北楡病院(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | http://meetinglibrary.asco.org/content/174622-195 |
| Results | RR and disease control rate (DCR) were 1.3% and 29.6%, respectively. Median PFS and median survival time (MST) were 2.1 and 6.3 months. |
| Other related information | Retrospective Cohort Study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024078 |